The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SCYX | -42.98% | -91.76% | -39.27% | -99% |
| S&P | +16.89% | +84.17% | +12.98% | +269% |
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
No news articles found for SCYNEXIS.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $334.00K | -49.4% |
| Market Cap | $32.28M | -42.8% |
| Market Cap / Employee | $1.15M | 0.0% |
| Employees | 28 | 0.0% |
| Net Income | -$8,591.00K | -205.9% |
| EBITDA | -$8,405.00K | 18.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $14.88M | -49.0% |
| Accounts Receivable | $0.00K | -100.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.82M | -20.3% |
| Short Term Debt | $463.00K | -96.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -33.71% | -4.3% |
| Return On Invested Capital | -50.21% | 31.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$8,724.00K | -1240.4% |
| Operating Free Cash Flow | -$8,724.00K | -1240.4% |
| Metric | Q1 2024 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 0.79 | - | |||
| Price to Book | 0.78 | 0.66 | 0.52 | 0.68 | -29.76% |
| Price to Sales | 12.27 | 17.90 | 10.30 | 13.10 | 54.96% |
| Price to Tangible Book Value | 0.78 | 0.66 | 0.52 | 0.68 | -29.76% |
| Enterprise Value to EBITDA | -0.31 | -0.99 | 0.94 | -0.32 | -82.63% |
| Return on Equity | -33.3% | -43.5% | -37.2% | -53.3% | 10.05% |
| Total Debt | $16.27M | $2.49M | $2.39M | $2.28M | -85.63% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
